• News
  • Ongoing dialogue: with Japanese pharma indust...
News - published on 03 Jun 2016

Ongoing dialogue: with Japanese pharma industry and at OECD Responsible Business Forum

From June 6–9, Executive Director, Jayasree K. Iyer, will be in Tokyo to follow up on the Foundation’s recent dialogue with Japanese pharmaceutical companies, and to meet with representatives of the Japanese Ministry of Foreign Affairs and the Ministry of Health. The dialogue, which took place in January, focuses on the role for the pharmaceutical industry and other stakeholders in the access-to-medicine space, as well as on opportunities for Japanese pharmaceutical companies to support the global health agenda.

At the 2016 GHIT Annual Partners Meeting

A central item on Jayasree’s itinerary is the 2016 Annual Partners Meeting of the Global Health Innovative Technology Fund (GHIT). The theme of this year’s meeting is on-the-ground innovation and impact, with a focus on the value of cross-sector collaboration for global health R&D. Speakers will also share the progress of key R&D projects being coordinated by GHIT, namely the development of a new paediatric formulation for treating schistosomiasis and the clinical progress of malaria vaccine candidate BK-SE36.

At the OECD Global Forum on Responsible Business Conduct

On June 9 in Paris, the Foundation’s Deputy Director of Strategy, Damiano de Felice, will chair a panel at the 2016 OECD Global Forum on Responsible Business Conduct. The panel will discuss responsible business conduct for pharmaceutical companies in light of SDG 3: “to ensure healthy lives and promote well-being for all”. The event will take place on the 40th anniversary of the OECD Guidelines for Multinational Enterprises, far-reaching recommendations that provide voluntary principles and standards for responsible business conduct.



Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.